The world of type 2 diabetes drugs is wacky indeed. While Amylin’s long-acting version of Byetta — called Bydureon and predicted by many experts to become a blockbuster — is still held up at FDA, the agency approved a new oral drug earlier this month that is reportedly unremarkable except in the lawsuit it has spurred.
The drug is called linagliptin, brand name Tradjenta, a new oral DPP-4 inhibitor from Eli Lilly and Boehringer that…
Read more »
By
AmyT on
January 24, 2011
I can’t help it. This reminds me of the movie City Slickers, in which one of the characters has messed up his life, and his friends tell him he’s getting a “do-over.” The young company Dance Pharmaceuticals, based in downtown San Francisco, is basically on a mission to salvage the good parts of Pfizer’s failed inhaled insulin Exubera (not the awkward delivery device!) and launch a second coming of the base product that is “simpler,…
Read more »
By
AmyT on
September 23, 2010
Earlier this week, Novo Nordisk released results of a sweeping new survey about how patients — both type 1 and type 2 — struggle with insulin therapy, and what doctors accredit that to.
Entitled the Global Attitudes of Patients and Physicians in Insulin Therapy (GAPPTM), the survey was conducted among almost 3,000 physicians and patients in eight countries “with the objective to learn what they perceive to be the biggest functional and emotional unfulfilled needs…
Read more »
Admittedly, I’m a bit tardy here in publishing the final installment of my Winter Olympics conversations with cross-country skier Kris Freeman. He has type 1 diabetes and was America’s best hope for a medal in his sport in Vancouver this year — but alas, things did not go well for Kris this time around. He suffered a BG low in the 15k, his best event; fell far behind in the 30k; and ended up dropping…
Read more »
By
AmyT on
April 27, 2009
IDEO is the world-renown design firm that transformed Kaiser Permanente’s modus operandi. They made the cover of BusinessWeek a few years ago. They’ve won scores of design competitions themselves.
So needless to say, we’re delighted to have them on board for the DiabetesMine Design Challenge, open for submissions until May 1, 2009 (so get movin’!). IDEO Senior Design Strategist John Lai is one of our judges this year, and two of our Design Challenge winners…
Read more »
